Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy

Southern Medical Journal

Volumn 104, Issue 12, 2011, Pages 781-788

  Stine, Jonathan G ^a   Bass, Michael ^a   Ibrahim, Dalia ^a   Khokhar, Omar S ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

dermatology; hepatitis B reactivation; immunosuppression; psoriasis; tumor necrosis factor inhibitors

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; AWARENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DRUG PACKAGING; HEPATITIS; HEPATITIS B; HUMAN; INFECTION RISK; MEDICAL EDUCATION; MEDICAL PRACTICE; PATIENT MONITORING; PRACTICE GUIDELINE; PSORIASIS; QUESTIONNAIRE; RISK ASSESSMENT; SCREENING TEST; SIDE EFFECT; SKIN INFLAMMATION; VIRUS REACTIVATION;

AWARENESS; CROSS-SECTIONAL STUDIES; DERMATOLOGY; DRUG LABELING; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RECURRENCE; RISK FACTORS; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 81455127478     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318238b608     Document Type: Article

References (24)

1. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007;37:705Y712.
2. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254Y258.
3. Yang CH, Wu TS, Chiu CT. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007;157:587Y590.
4. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68Y69.
5. Tsai FC, Hsieh SC, Chen DS, et al. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006;51:1627Y1632.
6. Charbel HLJ. Hepatitis B reactivation during chemotherapy and other immunosuppression. In: Shetty K, Wu G, eds. Chronic Viral Hepatitis. 2nd ed. Totowa, NJ: The Humana Press, Inc; 2010: pp 307Y336.
7. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987Y1019.
8. Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010;28:508Y518.
9. Mease P. TNF-alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004;63:755Y758.
10. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94: 998Y1005.
11. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:3147Y3153.
12. Stine JG, Khokhar OS, Charalambopoulos J, et al. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken) 2010;62:704Y711.
13. Smith CH, Anstey AV, Barker JN, et al. British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486Y497.
14. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826Y850.
15. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851Y864.
16. Lebwohl M, Bagel J, Gelfand JM, et al. From the medical board of the national psoriasis foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94Y105.
17. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507Y539.
18. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1Y20.
19. Khokhar OS, Farhadi A, McGrail L, et al. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 2009;55:69Y75.
20. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1, 31.15.
21. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 2005;366:1367Y1374.
22. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005; 152:954Y960.
23. Sheehan KB. E-mail survey response rates: a review. J Comput Mediat Commun 2001;6:1Y20.
24. Keeter S, Kohut A, Miller A. Consequences of non-response in a large national telephone survey. Public Opin Q 2000;64:125.